DelMar Pharmaceuticals to present at Rodman and Renshaw conference

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced Tuesday it will be presenting at the 17th annual Rodman & Renshaw Global Investment Conference from Sept. 9-10 at the St. Regis Hotel in New York.

DelMar's President and CEO Jeffrey Bacha will present at 3:50 p.m. ET Sept. 9. Bacha will present a corporate overview, including recent progress of DelMar's Phase II clinical trial of VAL-083 for the treatment of refractory glioblastoma multiforme and future plans to initiate clinical trials with VAL-083 as a potential treatment for non-small cell lung cancer and other solid tumors in collaboration with Guangxi Wuzhou Pharmaceutical Co., Ltd.

DelMar also recently announced that it will present the next formal update of its clinical trial in GBM at the 2nd International Symposium on Clinical and Basic Research in Glioblastoma, held Sept. 9-12 in Toledo, Spain.

A live webcast of the presentation will be available by accessing the DelMar's IR Calendar in the Investors section of the company's website www.delmarpharma.com. A webcast replay will be available around two hours after the presentation ends and will be accessible for one month.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments.